Pediatrix Medical Group, Inc. (NYSE:MD) Shares Bought by Atria Investments Inc

Atria Investments Inc lifted its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 9.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,124 shares of the company’s stock after buying an additional 2,238 shares during the quarter. Atria Investments Inc’s holdings in Pediatrix Medical Group were worth $314,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its stake in Pediatrix Medical Group by 3.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock valued at $245,000 after acquiring an additional 1,088 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Pediatrix Medical Group by 7.4% during the first quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after purchasing an additional 1,167 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares during the last quarter. SummerHaven Investment Management LLC grew its stake in Pediatrix Medical Group by 3.8% in the second quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock worth $422,000 after purchasing an additional 2,069 shares in the last quarter. Finally, Bank of Montreal Can increased its holdings in Pediatrix Medical Group by 0.5% in the second quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock valued at $3,196,000 after buying an additional 2,083 shares during the last quarter. Institutional investors own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on MD shares. StockNews.com downgraded Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday. Truist Financial raised their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. Mizuho raised their price target on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, UBS Group boosted their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Pediatrix Medical Group presently has a consensus rating of “Hold” and an average price target of $16.10.

Pediatrix Medical Group Stock Performance

MD stock opened at $14.96 on Friday. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $16.41. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -4.91, a PEG ratio of 2.08 and a beta of 1.55. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The stock’s fifty day moving average is $12.84 and its two-hundred day moving average is $10.00.

Pediatrix Medical Group (NYSE:MD) last issued its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm had revenue of $511.20 million for the quarter, compared to the consensus estimate of $498.87 million. During the same period last year, the firm posted $0.29 EPS. Pediatrix Medical Group’s quarterly revenue was up .9% compared to the same quarter last year. On average, research analysts predict that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Insider Activity

In related news, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now directly owns 138,683 shares in the company, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,808 shares of company stock valued at $751,277. Insiders own 2.00% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.